✦ LIBER ✦

Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer

✍ Scribed by Joshua H. Petit; Ming-Hui Chen; Marian Loffredo; Brenda Sussman; Andrew A. Renshaw; Anthony V. D'Amico

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 155 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22243

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prostate cancer-specific mortality and t

Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer

✍ Karen E. Hoffman; Ming-Hui Chen; Brian J. Moran; Michelle H. Braccioforte; Danie 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

Cancer-specific mortality after radiatio

Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer

✍ Henry K. Tsai; Ming-Hui Chen; David G. McLeod; Peter R. Carroll; Jerome P. Richi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

## Abstract ## BACKGROUND. The presence of multiple determinants of aggressive cancer biology may impact prostate cancer‐specific mortality (PCSM) rates compared with fewer factors. The authors estimated PCSM after radiation therapy with short‐course androgen suppression therapy (RT+AST) or radica

Prostate cancer-specific mortality after

Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors

✍ Anthony V. D'Amico; Ming-Hui Chen; William J. Catalona; Leon Sun; Kimberly A. Ro 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 292 KB

## Abstract ## BACKGROUND. Estimates of prostate cancer‐specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with ≥1 high‐risk factors. ## METHODS. The study cohort comprised 948 men who underwent RP (N = 660) or RT (N = 288) for localized p

Predictors of mortality after androgen-d

Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer

✍ Neesha A. Rodrigues; Ming-Hui Chen; William J. Catalona; Kimberly A. Roehl; Jero 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

Pretreatment prostate-specific antigen v

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

✍ David Palma; Scott Tyldesley; Tom Pickles; for the Prostate Cohort Outcomes Init 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

## Abstract ## BACKGROUND In men with prostate cancer, pretreatment prostate‐specific antigen (PSA) velocity (PSAV) has been demonstrated as a predictor of biochemical and survival outcomes in patients undergoing radical prostatectomy (RP). The utility of pretreatment PSAV in predicting outcomes a

Pretreatment serum prostate-specific ant

Pretreatment serum prostate-specific antigen (PSA) level and PSA doubling times (PSADT) in black and white men with prostate cancer referred for radiation therapy

✍ W. Robert Lee; Gerald E. Hanks; Alexandra Hanlon; Timothy E. Schultheiss 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 1 views

Numerous racial differences have been reported for carcinoma of the prostate diagnosed in African-American (AA) men when compared to whites. These differences include: (1) a higher incidence in AA compared to whites, (2) a more advanced stage at diagnosis in A4, and (3) higher mortality rates in AA